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Abstract
We investigated the effect of a synthetic cannabinoid, WIN 55,212-2 on excitatory postsynaptic currents (EPSCs) evoked by stimulation of
Schaffer collaterals in CA1 pyramidal cells. Bath application of WIN 55,212-2 reduced the amplitude of EPSCs in dose-dependent manner
tested between 0.01 nM and 30 mM. In rats and mice, this cannabinoid ligand inhibited excitatory synapses in two steps at the nM and mM con-
centrations. When the function of CB1 cannabinoid receptors (CB1R) was impaired, either by the application of a CB1R antagonist AM251, or
by using CB1R knockout mice, WIN 55,212-2 in mM concentrations could still significantly reduced the amplitude of EPSCs. WIN 55,212-2
likely affected the efficacy of excitatory transmission only at presynaptic sites, since both at low and high doses the paired pulse ratio of EPSC
amplitude was significantly increased. The inactive enantiomer, WIN 55,212-3, mimicked the effect of WIN 55,212-2 applied in high doses. In
further experiments we found that the CB1R-independent effect of 10 mM WIN 55,212-2 at glutamatergic synapses was fully abolished, when
slices were pre-treated with u-conotoxin GVIA, but not with u-agatoxin IVA.
These data suggest that, in the hippocampus, WIN 55,212-2 reduces glutamate release from Schaffer collaterals solely via CB1Rs in the nM
concentration range, whereas in mM concentrations, WIN 55,212-2 suppresses excitatory transmission, in addition to activation of CB1Rs, by
directly blocking N-type voltage-gated Ca2þ channels independent of CB1Rs.
 2007 Elsevier Ltd.
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The type 1 cannabinoid receptors (CB1Rs) have been shown
to control the release of different neurotransmitters, but the
mechanisms underlying the regulation of synaptic communica-
tion could substantially vary between brain regions (Freund
et al., 2003). Pharmacological results, suggesting a presynaptic
locus of action of cannabinoid receptor ligands, have been fully
supported by immunohistochemical data. Several studies dem-
onstrated at the electron microscopic level that CB1Rs deco-
rated both inhibitory and excitatory axon terminals (Katona
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Open access under CC BY license.et al., 1999, 2006; Kawamura et al., 2006). In addition, recent
high-resolution quantitative studies established that CB1Rs
were found all around the axon membrane, but were enriched
in the perisynaptic annulus and on preterminal segments,
whereas immunolabelling was weaker in the synaptic active
zone (Nyiri et al., 2005; Kawamura et al., 2006). This subcellu-
lar distribution of CB1Rs might imply an action on several reg-
ulatory mechanisms of transmitter release, including the control
of Ca2þ entry via voltage-dependent Ca2þ channels (primarily
by receptors located in the perisynaptic annulus), the reduction
of axonal conduction (by receptors present on the preterminal
segments), or a direct action on exocytosis (Wilson et al.,
2001; Diana and Marty, 2003).
In spite of the direct anatomical evidence, several
pharmacological observations suggest that some synthetic
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a CB1R-independent action on synaptic glutamate release.
This possibility has been fuelled primarily by experiments using
CB1R knockout mice. Our laboratory was the first to show that,
in the absence of CB1Rs, WIN 55,212-2 was still able to reduce
excitatory, but not inhibitory postsynaptic currents in CA1 pyra-
midal neurons (Ha´jos et al., 2001). Moreover, WIN 55,212-2
was more potent in suppressing GABAergic than glutamatergic
transmission (Hoffman and Lupica, 2000; Ohno-Shosaku et al.,
2002; Ha´jos and Freund, 2002), providing further support for
the possible presence of CB1R-independent binding site at ex-
citatory synapses. Importantly, AM251, a CB1R antagonist pre-
vented the reduction of synaptic inhibition after application of
WIN 55,212-2, whereas glutamatergic transmission could still
be suppressed by about 50% in the presence of AM251 (Ha´jos
and Freund, 2002). In contrast to the above findings showing
that hippocampal glutamatergic synapses were effectively reg-
ulated independent of CB1Rs, electrophysiological data from
other groups suggested that CB1Rs were solely responsible for
the cannabinoid modulation of excitatory synaptic transmission
in the hippocampus (Ohno-Shosaku et al., 2002; Domenici
et al., 2006; Takahashi and Castillo, 2006).
To shed light on the reasons behind the contradictory
findings regarding the involvement of CB1R-dependent vs.
-independent mechanisms in the regulation of hippocampal ex-
citatory synapses, we re-examined the effect of WIN 55,212-2
on monosynaptically evoked excitatory postsynaptic currents
(EPSCs) in CA1 pyramidal cells. All these experiments were
performed in a modified submerged recording conditions
(Ha´jos et al., 2005).
2. Methods
Experiments were carried out according to the guidelines of the institutional
ethical code and the Hungarian Act of Animal Care and Experimentation (1998.
XXVIII. section 243/1998.). Male Wistar rats (14e18 days old), as well as wild
type and CB1R knockout mice (15e25 days old, CD1 strain) were used. The an-
imals were deeply anaesthetized with isoflurane followed by decapitation. After
opening the skull, the brain was quickly removed and immersed into ice-cold
cutting solution containing (in mM: sucrose 252; KCl 2.5; NaHCO3 26; CaCl2
0.5; MgCl2 5; NaH2PO4 1.25; glucose 10). The solution had been bubbled
with 95% O2/5% CO2 (carbogen gas) for at least 30 min before use. Thick hor-
izontal slices (350 mm from mice and 400 mm from rats) were prepared using
a Leica VT1000S Vibratome. The CA3 region was removed to prevent epileptic
burst firings. The slices were stored in an interface type chamber containing
ACSF (in mM: 126 NaCl, 2.5 KCl, 26 NaHCO3, 2 CaCl2, 2 MgCl2, 1.25
NaH2PO4, and 10 glucose) at room temperature for at least 1 h before recording.
After the initial incubation period, slices were transferred individually into a sub-
merged type recording chamber.
Whole-cell patch-clamp recordings were obtained at 30e32 C from CA1
pyramidal cells visualized by infrared DIC videomicroscopy (Zeiss Axio-
scope, Germany). Patch electrodes were pulled from borosilicate glass capil-
laries with an inner filament (1.5 mm O.D.; 1.12 mm I.D., Hilgenberg,
Germany) using a Sutter P-87 puller. Electrodes (~3e6 MU) were filled
with a solution containing (in mM) 80 CsCl, 60 Cs-gluconate, 3 NaCl, 1
MgCl2, 10 HEPES, 2 Mg-ATP, and 5 QX-314 (pH 7.2e7.3 adjusted with
CsOH; osmolarity 275e290 mOsm). Excitatory postsynaptic currents (EPSCs)
were recorded at a holding potential of 65 mV. Slices were perfused with
ACSF containing 70e100 mM picrotoxin to block inhibitory neurotransmis-
sion. The solution was bubbled with carbogen gas at room temperature and
perfused at a flow rate of 3e4.5 ml/min in a slice chamber optimized for lam-
inar flow to ensure the stability of the amplitude of evoked currents and a betteroxygenation of submerged slices (Ha´jos et al., 2005). To evoke EPSCs, the
stimulating electrode was placed in the stratum radiatum of CA1. Pairs of elec-
trical stimuli separated by 50 ms were delivered via a theta glass pipette
(Sutter Instrument Company, Novato, CA) filled with ACSF at 0.1 Hz using
a Supertech timer and isolator (Supertech LTD, Pe´cs, Hungary, http://www.su-
perte.ch). Access resistances (between 4 and 18 MU, compensated 65e70%)
were frequently monitored and remained constant (20%) during the period
of analysis. Signals were recorded with a Multiclamp 700A (Molecular De-
vices, Sunnyvale, CA), filtered at 2 kHz, digitized at 6 kHz (National Instru-
ments PCI-6024E A/D board, Austin, TX), and analyzed off-line with the
EVAN program (courtesy of Prof. I. Mody, UCLA, CA).
The drug was perfused in a given concentration until the maximal effect
was reached. The time needed for maximal inhibition was usually 6e8 min.
To avoid the possible effect of a changing pH, we added the same amount
of HCl to the control solution. The concentration response relationship for
WIN 55,212-2 was obtained as follows: control EPSC amplitudes in a
2e3 min time window were compared to those measured after 10 min drug
application for the same period of time. Only those experiments were included
that had stable amplitudes at least for 10 min before drug application. After
each experiment, the tubing made of Teflon was washed with ethanol for
10 min and with ACSF for 15 min. Each data point represents the mean 
SEM of the maximal inhibition of the evoked EPSCs (n ¼ 3e7). EC50
values were estimated by fitting a curve to the points of the dose response
plots obtained in rats or wild type mice using the equation of f(x) ¼
a/(1 þ exp((x  c)/b)) þ (100  a)/(1 þ exp((x  e)/d )), where ‘c’ and
‘e’ give the values for high and low affinity binding sites, respectively. The
data points obtained in the presence of AM251 or in CB1 knockout mice
were fitted by the equation of f(x) ¼ a/(1 þ exp((x  c)/b)), where ‘c’ gives
the value of EC50. The curve fitting was done using Origin 7.5 (OriginLab
Corporation, MA). The paired pulse ratio was calculated from the mean
amplitude of the second EPSCs divided by the mean amplitude of the first
EPSCs. The paired pulse ratio after drug treatment was compared with the
control using Wilcoxon matched pairs test in STATISTICA 6.1 (Statsoft, Inc.,
Tulsa, OK). Data are presented as mean  SEM.
Picrotoxin, WIN 55,212-2 and WIN 55,212-3 were purchased from Sigma-
Aldrich, AM251 was obtained from Tocris, while u-conotoxin GVIA and
u-agatonix IVA from Alomone Labs. For all experiments, WIN-55,212-2
was dissolved in 0.1N HCl giving a 20 mM stock solution stored at 4 C.
AM251 was dissolved in DMSO (100 mM) and stored at 20 C. WIN
55,212-3 dissolved in DMSO (100 mM) was stored at 4 C. From these stock
solutions, the final dilution of drugs was done in ACSF containing picrotoxin
under constant stirring and the prepared solution was bath applied. In control
solutions, the vehicle was diluted in the same concentration as in the solutions
containing drugs. Bovine serum albumin (BSA) was added in a concentration
of 0.1 mg/ml to the solutions used for experiments with WIN 55,212-3.
3. Results
The effects of the cannabinoid agonist WIN 55,212-2 on
EPSCs evoked by focal stimulation of Schaffer collaterals
were measured in hippocampal CA1 pyramidal cells. First we
performed concentration response analyses for the inhibitory ef-
fects of WIN 55,212-2 on evoked EPSC in rat slices (Fig. 1a).
WIN 55,212-2 bath applied between the concentrations of
0.1 nM and 30 mM suppressed the amplitude of EPSCs in two
steps. The apparent EC50 values from the fitted curve were
2.91 nM and 3.77 mM (Fig. 1c). Then we investigated the
WIN 55,212-2-sensitivity of EPSCs, when AM251, a CB1R
specific antagonist was added to the bath solution in the concen-
tration of 2 mM. In spite of the presence of AM251, the canna-
binoid agonist could still reduce the amplitude of evoked
currents, but only in the mM range (Fig. 1a). The estimated
EC50 value for this effect was 1.69 mM (Fig. 1c).
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tion response relationship for the WIN 55,212-2-induced reduc-
tion of evoked EPSCs in mouse slices (Fig. 1b). The sensitivity
of synaptic currents for WIN 55,212-2 was tested between the
concentrations of 0.01 nM and 30 mM. Similar to that observed
in rat slices, the cannabinoid agonist also decreased the ampli-
tude of EPSCs in two steps. The EC50 values estimated by fitting
a curve to the points of the dose response plot were 1.91 nM and
12.1 mM (Fig. 1c). To reveal whether WIN 55,212-2 could still
suppress excitatory transmission in CB1R-independent manner
in mice, we examined the effect of the cannabinoid agonist in
CB1R knockout animals. As shown in Fig. 1b, WIN 55,212-2
effectively reduced the amplitude of EPSCs, but only in the
mM range. The apparent EC50 value estimated from the curve
fitting was 8.32 mM (Fig. 1c).
These results obtained both in rats and mice suggest that
WIN 55,212-2 in nM concentrations inhibits excitatory synaptic
transmission exclusively via CB1Rs, whereas in mM concentra-
tions it has a mixed CB1R-dependent and -independent effect on
glutamatergic transmission at Schaffer collateral synapses.
By a comparison of the paired-pulse ratios of evoked
EPSCs, we next investigated whether the CB1R-independent
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Fig. 1. The suppression of excitatory postsynaptic currents by WIN 55,212-2
via CB1R-dependent and independent mechanisms in rats and mice. a, In rat
slices, representative averaged records of 6e12 consecutive events taken
before (black) and after 10 min of WIN 55,212-2 application (gray) in the
absence or presence of 2 mM AM251 are superimposed. b, Averaged record-
ings of 8e12 consecutive EPSCs taken before (black) and after application
of WIN 55,212-2 (WIN-2; gray) in wild type mice (WT) or in CB1R knock-
outs (KO). The concentration of the CB1R agonist is indicated for each
example. Scale bars are 25 pA and 5 ms. c, Concentration-response relation-
ship of WIN 55,212-2 in the inhibition of evoked EPSCs recorded in CA1
pyramidal cells in rats (left panel) and mice (right panel). The agonist inhibited
the amplitude of events in two steps in rats and wild type mice, whereas only
high doses of WIN 55,212-2 reduced synaptic currents in the presence of
AM251 or in CB1R knockout mice. Data obtained after application of the in-
active enantiomer WIN 55,212-3 (WIN-3) are also included on the left graph.action of WIN 55,212-2 is presynaptic, i.e. whether it is inhib-
iting glutamate release similar to that seen earlier for CB1Rs.
We first examined the effect of 10 nM WIN 55,212-2 on the
paired-pulse ratio in rats and wild type mice. After drug appli-
cation, the ratio significantly increased to 132.5  9.4% of
control in rats and to 129.5  14.2% of control and mice
(Fig. 2; n ¼ 5 each, p < 0.05, Wilcoxon test). These data are
in line with both electrophysiological and anatomical results,
suggesting a presynaptic locus of CB1R-dependent action.
To check that the changes in the paired-pulse ratio were due
to the activation of CB1Rs, we contrasted these values before
and after the application of 10 nM WIN 55,212-2 in the pres-
ence of AM251. As expected, the paired-pulse ratio was not
altered (98.4  6.1%, n ¼ 6; p > 0.1, Wilcoxon test; Figs.
2a,c). Next we compared the paired-pulse ratio before and
after the application of 30 mM WIN 55,212-2. The ratio of
evoked currents was significantly increased to 145.1  5.3%
of control in rat slices (n ¼ 5; p < 0.05, Wilcoxon test) and
to 141.3  11.8% in slices from wild type mice (n ¼ 7;
p < 0.05, Wilcoxon test). To reveal that the CB1R-independent
action of WIN 55,212-2 also modifies transmitter release, we
investigated the paired-pulse ratio after application of 30 mM
WIN 55,212-2, while 2 mM AM251 was included in the
bath. The ratio of the amplitude of evoked EPSCs still signif-
icantly increased, to 136.4  8.4% of control (Figs. 2a,c;
n ¼ 7, p < 0.05, Wilcoxon test). Similar to these results,
30 mM WIN 55,212-2 also raised the paired pulse ratio to
121.1  2.9% of control in CB1R knockout mice (Figs. 2b,c;
n ¼ 6, p < 0.05, Wilcoxon test). Thus, the CB1R-independent
effect of WIN 55,212-2 also appears to be presynaptic, reduc-
ing glutamate release from Schaffer collateral terminals.
As reported earlier (Shen and Thayer, 1998), WIN 55,212-2
in mM concentrations could directly alter Ca2þ currents inde-
pendent of CB1Rs, an effect that could be mimicked by its
inactive enantiomer WIN 55,212-3. To test whether at glutama-
tergic axon terminals a similar mechanism would be responsi-
ble for the reduction of EPSC amplitude, WIN 55,212-3 was
bath applied in two different concentrations to rat slices. This
inactive enantiomer significantly suppressed the amplitude of
evoked EPSCs by 42.8  10.7% (n ¼ 5) and 54.7  12.1%
(n ¼ 3) in 10 mM and 30 mM concentrations, respectively
(Fig. 1c). These effects were indistinguishable from those
values, which were obtained in the presence of AM251 after
application of 10 mM (46.9  7.8%; n ¼ 5) or 30 mM (59.6 
3.2%; n ¼ 4) WIN 55,212-2 ( p > 0.1, ManneWhitney
U-test). These results suggest that the CB1R-independent ac-
tion of WIN 55,212-2 on glutamatergic transmission might
be due to the direct inhibition of Ca2þ entry into the pre-
synaptic boutons.
To get deeper insight into the mechanisms underlying the
CB1R-independent effects of WIN 55,212-2, we specifically
examined the involvement of voltage-gated Ca2þ channels in
this process. Rat slices were pre-incubated either in 250 nM
u-agatoxin IVA (a specific blocker of P/Q-type Ca2þ chan-
nels) or in 250 nM u-conotoxin GVIA (a specific inhibitor
of N-type Ca2þ channels) at least for an hour. After placing
the pre-treated slices in the recording chamber, we bath
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Fig. 2. Both CB1R-dependent and -independent effects of WIN 55,212-2 enhance the paired-pulse facilitation of evoked EPSCs. a, In rat slices, the paired-pulse
ratio was similarly increased after application of WIN 55,212-2 (WIN-2) in low concentrations or in high concentrations, when 2 mM AM251 was present in the
bath, as seen on the scaled representative averages of 10e12 consecutive events before (black) and after (gray) the drug treatments. However, the paired pulse ratio
remained unchanged, when WIN 55,212-2 in 10 nM concentration was co-applied with AM 251. b, Averaged recordings of consecutive EPSCs taken before
(black) and after application of WIN 55,212-2 (gray) in wild type mice (WT) or in CB1R knockouts (KO) were scaled to indicate the enhancement of the
paired-pulse ratio. The stimulus artefacts were removed from the traces. c, The paired-pulse ratios (PPR) calculated from each recordings in control conditions
(ctr) and after drug application are presented for corresponding experiments.applied 10 mM WIN 55,212-2 in the presence of 2 mM
AM251. In slices pre-treated with u-agatoxin IVA, the ampli-
tude of EPSCs was reduced by 39.7  8.3% (n ¼ 4, p < 0.05,
Wilcoxon test; Fig. 3a), whereas there was no change in the
synaptic currents after application of WIN 55,212-2 in slices
pre-incubated with u-conotoxin GVIA (95.8  3.2% of con-
trol, n ¼ 6, p > 0.1, Wilcoxon test; Fig. 3b). The results of
these experiments suggest that the CB1R-independent action
of WIN 55,212-2 at glutamatergic synapses is mediated via
inhibition of N-type Ca2þ channels.
4. Discussion
Our data presented here demonstrate that excitatory synapses
of Schaffer collaterals in CA1 pyramidal cells are inhibited by
WIN 55,212-2 both via CB1R-dependent and independent
mechanisms. In low nM concentrations, this cannabinoid ligand
solely acts as a CB1R agonist reducing glutamate release. In
contrast, WIN 55,212-2 in the mM range suppresses glutamater-
gic synaptic transmission via activation of CB1Rs as well as
inhibiting N-type Ca2þ channels independent of CB1Rs.
Shen et al., (1996) were the first to show that excitatory
transmission in the hippocampus could be reduced by WIN
55,212-2, a finding that has been strengthened later by several
other laboratories (Misner and Sullivan, 1999; Al-Hayani and
Davies, 2000; Ha´jos and Freund, 2002; Ohno-Shosaku et al.,
2002; Hoffman et al., 2003). Similarly to that observed in
the hippocampus, WIN 55,212-2 was also shown to suppress
excitatory synapses in other brain regions, including the cere-
bellum (Levenes et al., 1998; Takahashi and Linden, 2000),
neocortex (Domenici et al., 2006), basolateral amygdala
(Azad et al., 2003; Domenici et al., 2006), or striatum (Gerde-
man and Lovinger, 2001; Huang et al., 2001). In earlierstudies, the lack of immunostaining for CB1Rs at excitatory
terminals (Katona et al., 1999; Ha´jos et al., 2000), taken to-
gether with experiments showing that WIN 55,212-2 could
significantly reduce glutamate release in CB1R knockouts (Ha´jos
et al., 2001; Kofalvi et al., 2003), fuelled the concept that
distinct cannabinoid receptors control synaptic excitation and
inhibition. This interpretation was supported by the unequivo-
cal demonstration of high densities of CB1Rs on GABAergic
axons, while adjacent glutamatergic terminals remained nega-
tive (Katona et al., 1999; Ha´jos et al., 2000; Nyiri et al., 2005),
as well as by the complete disappearance of cannabinoid sen-
sitivity of IPSCs in CB1R knockouts (Ha´jos et al., 2000, 2001;
Varma et al., 2001; Wilson et al., 2001). Moreover, Ha´jos and
Freund (2002) showed that AM251 could fully antagonise the
effect of WIN 55,212-2 at GABAergic, but not at glutamater-
gic synapses, further strengthening the existence of a novel
cannabinoid-sensitive binding site at hippocampal excitatory
synapses. Recently this concept was substantially challenged
both by anatomical and electrophysiological experiments, in-
cluding studies from our own laboratory. First, using a different
type of antibody, CB1Rs were convincingly shown to be pres-
ent on glutamatergic terminals, although in much smaller
quantities than on GABAergic axons (Katona et al., 2006;
Kawamura et al., 2006). Specificity of the staining has been
confirmed in CB1R knockout tissue. Second, excitatory
transmission was found to be insensitive to the application
of WIN 55,212-2 in distinct strains of transgenic mice lacking
CB1Rs (Ohno-Shosaku et al., 2002; Domenici et al., 2006;
Takahashi and Castillo, 2006). The discrepancy between earlier
and recent data might be resolved by the present findings sug-
gesting that at low nM concentrations WIN 55,212-2 specifi-
cally activates CB1Rs, whereas in the mM range the agonist
could further reduce glutamate release via direct inhibition
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Fig. 3. CB1R-independent effect of WIN 55,212-2 at excitatory synapses is mediated via inhibition of N-type Ca
2þ channels. Rat slices were pre-treated with
250 nM u-agatoxin IVA or with u-conotoxin GVIA at least for an hour before the experiments. To block CB1Rs, 2 mM AM251 was included in the solution.
a, In slices pre-incubated with u-agatoxin IVA, 10 mM WIN 55,212-2 effectively reduced the amplitude of evoked EPSCs as shown on the averaged recordings
of 8e10 consecutive events before (right) and after (left) drug application. The bottom graph calculated from 4 experiments indicates that wash-in of 10 mM WIN
55,212-2 significantly suppressed the EPSC amplitude. b, In contrast, when 10 mM WIN 55,212-2 was applied onto slices that were pre-incubated in u-conotoxin
GVIA, no change in the amplitude of EPSC was observed. Averaged traces before (right) and after (left) drug application are shown. The stimulus artefacts were
removed from the traces. Scale bars are 20 pA and 5 ms. The bottom plot obtained from 6 experiments shows that WIN 55,212-2 could not alter the glutamatergic
transmission, indicating that, independent of CB1Rs, N-type voltage-gated Ca
2þ channels are required for presynaptic inhibition by this cannabinoid compound
applied in high doses.of presynaptic Ca2þ entry independent of CB1Rs (present
study; Shen and Thayer, 1998; Kofalvi et al., 2007). This dif-
ference in the specificity of WIN 55,212-2 as a function of its
concentration can be noticed already in studies reported by the
Kano laboratory. WIN 55,212-2 in 100 nM caused a large re-
duction in the amplitude of EPSCs in wild type mice, but in
CB1R knockouts less then 5% suppression was found
(Ohno-Shosaku et al., 2002). However, in 2 mM concentration,
WIN 55,212-2 inhibited excitatory transmission by about 20%
in CB1R knockout mice, an effect that was unaltered in the
presence of CB1R antagonists (Kawamura et al., 2006).
Further support to the hypothesis that WIN 55,212-2 in mM
concentrations can reduce excitatory transmission via CB1R-
independent mechanisms come from the work of Hoffman
et al. (2005), where the authors showed that in the presence
of AM251, 3 mM WIN 55,212-2 significantly (appr. by 40%)
reduced excitation. This view, however, is not supported by
two recent studies using CB1R knockout animals, in which
5 mM WIN 55,212-2 was found to be completely ineffective
at excitatory synapses (Domenici et al., 2006; Takahashi and
Castillo, 2006). The explanation for these negative findings re-
mains to be investigated.
Another finding of the present study that deserves discus-
sion is that the effective concentration of WIN 55,212-2 that
significantly inhibited the amplitude of synaptic events in slice
preparations was 100 fold lower than it was earlier reported by
several laboratories using similar recording circumstances
(Takahashi and Linden, 2000; Robbe et al., 2001; Ha´jos and
Freund, 2002; Hoffman et al., 2005). Compared to earlier stud-
ies, we changed some conditions that could account for the
distinct efficacy of WIN 55,212-2, which allowed clearly sep-
arating CB1R-dependent and independent effects. The prepa-
ration and storage of slices, as well as the flow rate of thesolution during recordings was modified: slices were cut in
a sucrose containing solution and stored in an interface-type
chamber before recordings, and a higher flow rate was used
in the recording chamber, ensuring a better oxygenation of
the tissue (Ha´jos et al., 2005). Under these circumstances,
the amplitude of evoked synaptic currents became more stable,
and, more importantly, the efficacy of WIN 55,212-2 to sup-
press excitatory synapses was comparable with those mea-
sured in cell cultures (Ohno-Shosaku et al., 2002) or binding
assays (Felder et al., 1995).
Several studies in different brain regions suggested that the
CB1R-independent effect of WIN 55,212-2 might significantly
alter synaptic communication among neurons (Ha´jos et al.,
2001; Pistis et al., 2004; Kofalvi et al., 2005; Matyas et al.,
2006), presumably through a direct blockade of Ca2þ entry
at the presynaptic terminals (Shen and Thayer, 1998; Kofalvi
et al., 2007). In the present study, we provided evidence that
the CB1R-independent effect of WIN 55,212-2 at glutamater-
gic synapses was mediated by inhibiting N-type Ca2þ
channels.
The question arises whether WIN 55,212-2 in high doses
could also alter GABAergic transmission independent of
CB1Rs, since GABA release from CB1R-expressing axon ter-
minals is known to depend on N-type Ca2þ channel activation
(Wilson et al., 2001). Indeed, we found that in CB1R knockout
mice 10 mM WIN 55,212-2 substantially reduced the ampli-
tude of IPSCs to 62.8  20.5% of control (n ¼ 4). In contrast,
when CB1R function was intact, both low and high doses of
WIN 55,212-2 led to a comparable reduction of IPSC ampli-
tudes (in 3 nM: 47.9  15.4% of control, n ¼ 4; in 10 mM:
45.2  19.7% of control, n ¼ 4), similar to results obtained
earlier (Ha´jos and Freund, 2002). The reason why WIN
55,212-2 in 10 mM concentration did not result in an
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functional CB1Rs may be explained by the fact that CB1R-
dependent inhibition of GABAergic currents is entirely due to
blocking N-type Ca2þ channels, which occludes the CB1R -in-
dependent action of WIN 55,212-2 directly on the same Ca2þ
channels. Testing this hypothesis, and other novel aspects of
cannabinoid modulation of GABAergic transmission is the
subject of another line of investigations in our laboratory.
The question arises whether at glutamatergic synapses, un-
der some experimental conditions, endocannabinoids can re-
duce the efficacy of neurotransmission via CB1R-dependent
and -independent mechanisms, similar to high concentrations
of WIN 55,212-2, which can modify Ca2þ entry directly.
Some results indeed imply that endocannabinoids could di-
rectly inhibit different types of voltage-gated Ca2þ channels
independent of CB1Rs (Chemin et al., 2001; Fisyunov et al.,
2006), yet other data suggest that endocannabinoids released
upon depolarization of a postsynaptic neuron (or exogenously
applied) are unable to suppress excitatory transmission in
CB1R knockout mice (Ohno-Shosaku et al., 2002; Straiker
and Mackie, 2005, but see Rouach and Nicoll, 2003). Never-
theless, the importance of identifying a CB1R-independent
binding site for WIN 55,212-2 as N-type Ca2þ channels at
excitatory terminals lies in resolving some contradictions in
pharmacological and behavioural studies that emerged partly
due to the use of WIN 55,212-2 in widely varying concentra-
tions (see a thorough discussion of this issue in Haller et al.,
2007).
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